32097
依托考昔
VETRANAL®, analytical standard
别名:
5-氯-3-[4-(甲磺酰基)苯基]-2-(2-甲基-5-吡啶基)吡啶, 5-氯-6′-甲基-3-[4-(甲磺酰基)苯基]]-2,3′-联吡啶
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H15ClN2O2S
化学文摘社编号:
分子量:
358.84
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
8073797
InChI
1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3
SMILES string
CC1=NC=C(C2=C(C3=CC=C(S(C)(=O)=O)C=C3)C=C(Cl)C=N2)C=C1
InChI key
MNJVRJDLRVPLFE-UHFFFAOYSA-N
grade
analytical standard
product line
VETRANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
storage temp.
2-8°C
Quality Level
Gene Information
human ... PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
Application
依托考昔已被用作参考标准品，用于通过液相色谱-串联质谱-常压化学电离分析法（LC-APCI/MS/MS）检测人血浆中的依托考昔。
有关合适仪器技术的更多信息，请参考产品′s分析证书。如需进一步支持，请联系技术服务。
General description
依托考昔是一种非甾体类环加氧酶-2（COX-2）选择性抗炎药，主要用于骨关节炎和类风湿性关节炎患者的治疗。
Legal Information
VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 2 Dermal - Acute Tox. 4 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
Yuhong Yuan et al.
Current pharmaceutical design, 13(22), 2237-2247 (2007-08-21)
Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the incidence of gastrointestinal (GI) adverse events (AEs) which occur with non-selective NSAIDs (ns-NSAIDs). Etoricoxib and lumiracoxib are regarded as second generation coxibs because of their higher COX-2 selectivity. There are
Kameran Daham et al.
The Journal of allergy and clinical immunology, 134(2), 306-313 (2014-01-28)
Prostaglandins that constrict and relax airways are synthesized in reactions catalyzed by either COX-1 or COX-2. It is not known whether selective inhibition of COX-2 makes asthmatic responses better or worse. To determine the effects of the selective COX-2 inhibitor
Katherine F Croom et al.
Drugs, 69(11), 1513-1532 (2009-07-29)
Etoricoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, approved in Europe for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Etoricoxib provided similar symptomatic relief to nonselective NSAIDs in patients with these conditions, and to celecoxib
Shruti Setia et al.
Pharmacological reports : PR, 64(3), 615-624 (2012-07-21)
Non-steroidal anti-inflammatory drugs (NSAIDs) act by inhibition of cyclooxygenase-2 (COX-2), which is overexpressed in cancer. The role of COX-2 and apoptosis were evaluated in 9,10-dimethylbenz(a)anthracene (DMBA)-induced lung cancer in rat and chemoprevention with indomethacin, a traditional NSAID and etoricoxib, a
E Chilet-Rosell et al.
Journal of public health (Oxford, England), 31(3), 434-445 (2009-03-17)
The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持